The 2021 Gastrointestinal (GI) cancers symposium will take place from January 15th to 17th and will offers new and innovating findings in GI cancer treatment, research, and care.
It will feature a wide array of topics delivered by experts in cancers of the esophagus, stomach, pancreas, small bowel, hepatobiliary tract, colon, rectum and anus.
Nanobiotix will be presenting data from the phase I dose-escalation study evaluating the potential of NBTXR3 for the treatment of HCC and liver metastases.
We are proud to have one abstract approved for the digital poster presentation that would be release on the ASCO website on January 11, 2021 at 5:00pm (EST).
